Targeting molecular pathways in endometrial cancer: A focus on the FGFR pathway

Cancer Treatment Reviews

Volumn 40, Issue 4, 2014, Pages 507-512

  Lee, Paula S ^a   Secord, Angeles Alvarez ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biologic therapies; Dovitinib; Endometrial cancer; FGFR signaling pathway; FGFR targeted therapy; Fibroblast growth factor receptor; Lenvatinib

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BGJ 398; BRIVANIB; BRIVANIB ALANINATE; CYTOTOXIC AGENT; DOVITINIB; FIBROBLAST GROWTH FACTOR RECEPTOR; GLUCOSE; LENVATINIB; PONATINIB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MODEL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CARCINOGENESIS; CLINICAL TRIAL (TOPIC); DRUG SAFETY; ENDOMETRIUM CANCER; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; LUNG EMBOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; NEUROLOGIC DISEASE; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THROMBOSIS;

BIOLOGIC THERAPIES; DOVITINIB; ENDOMETRIAL CANCER; FGFR SIGNALING PATHWAY; FGFR-TARGETED THERAPY; FIBROBLAST GROWTH FACTOR RECEPTOR; LENVATINIB;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, FIBROBLAST GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84896715470     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.11.004     Document Type: Review

References (69)

1. American Cancer Society. Cancer facts & figures 2013. [Accessed August 2, 2013]. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf.
2. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
3. National Cancer Institute. Surveillance epidemiology and end results. SEER stat fact sheets; corpus and uterus, NOS. [Accessed August 2, 2013]. http://www.seer.cancer.gov/statfacts/html/corp.html.
4. Carlson M.J., Thiel K.W., Yang S., Leslie K.K. Catch it before it kills: progesterone, obesity, and the prevention of endometrial cancer. Discov Med 2012, 14:215-222.
5. Pickar J.H. The endometrium-from estrogens alone to TSECs. Climacteric 2009, 12:463-477.
6. Reeves K.W., Carter G.C., Rodabough R.J., et al. Obesity in relation to endometrial cancer risk and disease characteristics in the Women's Health Initiative. Gynecol Oncol 2011, 121:376-382.
7. Zagouri F., Bozas G., Kafantari E., et al. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy?. Obstet Gynecol Int 2010, 2010:749579.
8. National Comprehensive Cancer Network. NCCN: clinical practice guidelines in oncology: uterine neoplasms. Version 1. 2013.
9. Humber C.E., Tierney J.F., Symonds R.P., et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. Ann Oncol 2007, 18:409-420.
10. Miller D., Filiaci V., Fleming G., et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2012, 125. [abstr. 771].
11. Sjoquist K.M., Martyn J., Edmondson R.J., Friedlander M.L. The role of hormonal therapy in gynecological cancers-current status and future directions. Int J Gynecol Cancer 2011, 21:1328-1333.
12. Yang S., Thiel K.W., De Geest K., Leslie K.K. Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med 2011, 12:205-212.
13. Bansal N., Yendluri V., Wenham R.M. The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies. Cancer Control 2009, 16:8-13.
14. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983, 15:10-17.
15. Chaudhry P., Asselin E. Resistance to chemotherapy and hormone therapy in endometrial cancer. Endocr Relat Cancer 2009, 16:363-380.
16. Hecht J.L., Mutter G.L. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006, 24:4783-4791.
17. Mutter G.L., Lin M.C., Fitzgerald J.T., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000, 92:924-930.
18. Cancer Genome Atlas Research Network, Kandoth C., Schultz N., Cherniack A.D., Akbani R., Liu Y., et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013, 497:67-73.
19. Oda K., Stokoe D., Taketani Y., McCormick F. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 2005, 65:10669-10673.
20. Catasus L., Gallardo A., Cuatrecasas M., Prat J. PIK3CA mutations in the kinase domain (exon 20) of uterine endometrial adenocarcinomas are associated with adverse prognostic parameters. Mod Pathol 2008, 21:131-139.
21. Okuda T., Sekizawa A., Purwosunu Y., et al. Genetics of endometrial cancers. Obstet Gynecol Int 2010, 2010:984013.
22. Konstantinova D., Kaneva R., Dimitrov R., et al. Rare mutations in the PIK3CA gene contribute to aggressive endometrial cancer. DNA Cell Biol 2010, 29:65-70.
23. Hayes M.P., Douglas W., Ellenson L.H. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol 2009, 113:370-373.
24. Saegusa M., Hashimura M., Yoshida T., Okayasu I. Beta-catenin mutations and aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 2001, 84:209-217.
25. Lax S.F., Kendall B., Tashiro H., Slebos R.J., Hedrick L. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 2000, 88:814-824.
26. Dutt A., Salvesen H.B., Chen T.H., et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 2008, 105:8713-8717.
27. Byron S.A., Gartside M.G., Wellens C.L., et al. Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 2008, 68:6902-6907.
28. Byron S.A., Gartside M., Powell M.A., et al. FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features. PLoS One 2012, 7:e30801.
29. Pollock P.M., Gartside M.G., Dejeza L.C., et al. Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 2007, 26:7158-7162.
30. Konecny G.E., Santos L., Winterhoff B., et al. HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer 2009, 100:89-95.
31. Basil J.B., Goodfellow P.J., Rader J.S., Mutch D.G., Herzog T.J. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 2000, 89:1758-1764.
32. Slomovitz B.M., Broaddus R.R., Burke T.W., et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004, 22:3126-3132.
33. Dedes K.J., Wetterskog D., Ashworth A., Kaye S.B., Reis-Filho J.S. Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 2011, 8:261-271.
34. Aghajanian C., Sill M.W., Darcy K.M., et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2011, 29:2259-2265.
35. Chen C.A., Cheng W.F., Lee C.N., et al. Cytosol vascular endothelial growth factor in endometrial carcinoma: correlation with disease-free survival. Gynecol Oncol 2001, 80:207-212.
36. Kamat A.A., Merritt W.M., Coffey D., et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007, 13:7487-7495.
37. Salvesen H.B., Iversen O.E., Akslen L.A. Independent prognostic importance of microvessel density in endometrial carcinoma. Br J Cancer 1998, 77:1140-1144.
38. Ornitz D.M., Xu J., Colvin J.S., et al. Receptor specificity of the fibroblast growth factor family. J Biol Chem 1996, 271:15292-15297.
39. Korc M., Friesel R.E. The role of fibroblast growth factors in tumor growth. Curr Cancer Drug Targets 2009, 9:639-651.
40. Werner S., Duan D.S., de Vries C., Peters K.G., Johnson D.E., Williams L.T. Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol 1992, 12:82-88.
41. Ahmad I., Iwata T., Leung H.Y. Mechanisms of FGFR-mediated carcinogenesis. Biochim Biophys Acta 2012, 1823:850-860.
42. Wollenhaupt K., Welter H., Brussow K.P., Einspanier R. Regulation of endometrial fibroblast growth factor 7 (FGF-7) and its receptor FGFR2IIIb in gilts after sex steroid replacements, and during the estrous cycle and early gestation. J Reprod Dev 2005, 51:509-519.
43. Wollenhaupt K., Welter H., Einspanier R., Manabe N., Brussow K.P. Expression of epidermal growth factor receptor (EGF-R), vascular endothelial growth factor receptor (VEGF-R) and fibroblast growth factor receptor (FGF-R) systems in porcine oviduct and endometrium during the time of implantation. J Reprod Dev 2004, 50:269-278.
44. Tsai S.J., Wu M.H., Chen H.M., Chuang P.C., Wing L.Y. Fibroblast growth factor-9 is an endometrial stromal growth factor. Endocrinology 2002, 143:2715-2721.
45. Moller B., Rasmussen C., Lindblom B., Olovsson M. Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle. Mol Hum Reprod 2001, 7:65-72.
46. Chen C., Spencer T.E., Bazer F.W. Fibroblast growth factor-10: a stromal mediator of epithelial function in the ovine uterus. Biol Reprod 2000, 63:959-966.
47. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-178.
48. Casanovas O., Hicklin D.J., Bergers G., Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
49. Ibrahimi O.A., Eliseenkova A.V., Plotnikov A.N., Yu K., Ornitz D.M., Mohammadi M. Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome. Proc Natl Acad Sci USA 2001, 98:7182-7187.
50. Ibrahimi O.A., Zhang F., Eliseenkova A.V., Itoh N., Linhardt R.J., Mohammadi M. Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 2004, 13:2313-2324.
51. Yu K., Herr A.B., Waksman G., Ornitz D.M. Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome. Proc Natl Acad Sci USA 2000, 97:14536-14541.
52. Wilkie A.O., Patey S.J., Kan S.H., van den Ouweland A.M., Hamel B.C. FGFs, their receptors, and human limb malformations: clinical and molecular correlations. Am J Med Genet 2002, 112:266-278.
53. Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A. The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation. Mol Cell Biol 2000, 20:516-522.
54. Cho J.Y., Guo C., Torello M., et al. Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia. Proc Natl Acad Sci USA 2004, 101:609-614.
55. Taniguchi F., Harada T., Sakamoto Y., et al. Activation of mitogen-activated protein kinase pathway by keratinocyte growth factor or fibroblast growth factor-10 promotes cell proliferation in human endometrial carcinoma cells. J Clin Endocrinol Metab 2003, 88:773-780.
56. Sales K.J., Boddy S.C., Williams A.R., Anderson R.A., Jabbour H.N. F-prostanoid receptor regulation of fibroblast growth factor 2 signaling in endometrial adenocarcinoma cells. Endocrinology 2007, 148:3635-3644.
57. Fujimoto J., Hori M., Ichigo S., Tamaya T. Expressions of the fibroblast growth factor family (FGF-1, -2 and -4) mRNA in endometrial cancers. Tumour Biol 1996, 17:226-233.
58. Gozgit J.M., Wong M.J., Moran L., et al. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 2012, 11:690-699.
59. Konecny G.E., Kolarova T., O'Brien N.A., et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther 2013, 12:632-642.
60. Gozgit J.M., Squillace R.M., Wongchenko M.J., et al. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol 2013, 71:1315-1323.
61. Byron S.A., Loch D.C., Pollock P.M. Fibroblast growth factor receptor inhibition synergizes with paclitaxel and doxorubicin in endometrial cancer cells. Int J Gynecol Cancer 2012, 22:1517-1526.
62. Mohammadi M., Froum S., Hamby J.M., et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 1998, 17:5896-5904.
63. Patel R.R., Sengupta S., Kim H.R., et al. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer 2010, 46:1537-1553.
64. Meng X., Yang S., Zhu D., Wang X., Thiel K.W., Leslie K.K. Strategies for molecularly enhanced chemotherapy in endometrial tumors with mutant p53. Am Assoc Cancer Res Annu Meeting 2013, [abstr. 3422].
65. Iclusig (ponatinib) prescribing information. 2012. [Accessed October 25, 2013]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203469lbl.pdf.
66. Powell M.A., Sill M.W., Goodfellow P.J., et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2012, 22. [abstr. E115].
67. Vergote I., Teneriello M., Powell M.A., et al. A phase II trial of lenvatinib in patients with advanced or recurrent endometrial cancer: angiopoietin-2 as a predictive marker for clinical outcomes. J Clin Oncol 2013, 31(Suppl.). [abstr. 5520].
68. Funahashi Y., Penson R.T., Powell M.A., et al. Analysis of plasma biomarker and tumor genetic alterations from a phase II trial of lenvatinib in patients with advanced endometrial cancer. J Clin Oncol 2013, 31(Suppl.). [abstr. 5591].
69. Konecny G.E., Finkler N., Garcia A., et al. Dovitinib as second-line therapy in patients with fibroblast growth factor receptor 2 (FGFR2)-mutated or non-mutated advanced and/or metastatic endometrial cancer (EC): A single-arm, multicenter, phase II study. J Clin Oncol 2013, 31(Suppl.). [abstr. TPS5616].